Effect of Single Dose Antenatal Betamethasone on Neonatal Respiratory Morbidity After Elective Cesarean
NCT ID: NCT04407975
Last Updated: 2020-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2020-05-29
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Caesarean and Corticotherapy
NCT00446953
Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean Section in Term Fetus
NCT01772381
Antenatal Corticosteroid in Elective Cesarean Section
NCT03396107
Dexamethasone Before Elective Cesarean Section at Term in Reducing Neonatal Respiratory Distress Syndrome
NCT04816097
Inhaled Salbutamol in Elective Caesarean Section
NCT01978418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Betamethasone
Patients will receive 14 mg (2 ml) intramuscular betamethasone
Betamethasone
A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
Placebo
Patients will receive an equivalent volume of normal saline
Placebo
A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Betamethasone
A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
Placebo
A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* between 37 and 40 weeks of pregnancy (as calculated from the first day of the last menstrual period)
Exclusion Criteria
* evidence of intrauterine infection,
* oligohydramnios,
* fetal congenital malformations,
* preeclampsia,
* maternal hypertension,
* severe fetal rhesus sensitization,
* antepartum hemorrhage,
* Intrauterine growth restriction
* preterm rupture of membranes
* preterm delivery
* previously received antenatal steroids less than one month ago
* those who decline to participate in the study.
17 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Makassed General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manal Hubeish
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manal Hubeish, MD
Role: PRINCIPAL_INVESTIGATOR
Makassed General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Makassed General Hospital
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
642020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.